Johnson & Johnson Goodwill and Intangible Assets 2010-2024 | JNJ
Johnson & Johnson goodwill and intangible assets from 2010 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
- Johnson & Johnson goodwill and intangible assets for the quarter ending June 30, 2024 were $83.975B, a 8.41% decline year-over-year.
- Johnson & Johnson goodwill and intangible assets for 2023 were $70.733B, a 5.1% decline from 2022.
- Johnson & Johnson goodwill and intangible assets for 2022 were $74.536B, a 8.7% decline from 2021.
- Johnson & Johnson goodwill and intangible assets for 2021 were $81.638B, a 9.08% decline from 2020.
Johnson & Johnson Annual Goodwill and Intangible Assets
(Millions of US $) |
| 2023 |
$70,733 |
| 2022 |
$74,536 |
| 2021 |
$81,638 |
| 2020 |
$89,795 |
| 2019 |
$81,282 |
| 2018 |
$78,064 |
| 2017 |
$85,134 |
| 2016 |
$49,681 |
| 2015 |
$47,393 |
| 2014 |
$49,054 |
| 2013 |
$50,745 |
| 2012 |
$51,176 |
| 2011 |
$34,276 |
| 2010 |
$32,010 |
| 2009 |
$31,185 |
Johnson & Johnson Quarterly Goodwill and Intangible Assets
(Millions of US $) |
| 2024-06-30 |
$83,975 |
| 2024-03-31 |
$70,902 |
| 2023-12-31 |
$70,733 |
| 2023-09-30 |
$71,145 |
| 2023-06-30 |
$91,686 |
| 2023-03-31 |
$93,023 |
| 2022-12-31 |
$74,536 |
| 2022-09-30 |
$73,719 |
| 2022-06-30 |
$76,574 |
| 2022-03-31 |
$79,355 |
| 2021-12-31 |
$81,638 |
| 2021-09-30 |
$83,345 |
| 2021-06-30 |
$86,063 |
| 2021-03-31 |
$86,798 |
| 2020-12-31 |
$89,795 |
| 2020-09-30 |
$81,313 |
| 2020-06-30 |
$81,303 |
| 2020-03-31 |
$80,809 |
| 2019-12-31 |
$81,282 |
| 2019-09-30 |
$81,137 |
| 2019-06-30 |
$82,993 |
| 2019-03-31 |
$78,348 |
| 2018-12-31 |
$78,064 |
| 2018-09-30 |
$79,339 |
| 2018-06-30 |
$80,402 |
| 2018-03-31 |
$83,514 |
| 2017-12-31 |
$85,134 |
| 2017-09-30 |
$85,877 |
| 2017-06-30 |
$86,176 |
| 2017-03-31 |
$54,310 |
| 2016-12-31 |
$49,681 |
| 2016-09-30 |
$50,813 |
| 2016-06-30 |
$47,798 |
| 2016-03-31 |
$47,688 |
| 2015-12-31 |
$47,393 |
| 2015-09-30 |
$47,267 |
| 2015-06-30 |
$48,510 |
| 2015-03-31 |
$48,370 |
| 2014-12-31 |
$49,054 |
| 2014-09-30 |
$47,940 |
| 2014-06-30 |
$49,111 |
| 2014-03-31 |
$49,821 |
| 2013-12-31 |
$50,745 |
| 2013-09-30 |
$51,319 |
| 2013-06-30 |
$50,041 |
| 2013-03-31 |
$50,358 |
| 2012-12-31 |
$51,176 |
| 2012-09-30 |
$50,567 |
| 2012-06-30 |
$50,611 |
| 2012-03-31 |
$34,496 |
| 2011-12-31 |
$34,276 |
| 2011-09-30 |
$34,274 |
| 2011-06-30 |
$34,621 |
| 2011-03-31 |
$34,813 |
| 2010-12-31 |
$32,010 |
| 2010-09-30 |
$32,443 |
| 2010-06-30 |
$31,087 |
| 2010-03-31 |
$31,776 |
| 2009-12-31 |
$31,185 |
| 2009-09-30 |
$31,653 |
| 2009-06-30 |
$28,872 |
| 2009-03-31 |
$28,923 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$399.964B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
